Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Buprenorphine
Drug ID BADD_D00310
Description Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain.[A186283,A186292] It is also commonly used as an alternative to [methadone] for the treatment of severe opioid addiction.[F4715,F4718] Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose combination product along with [naloxone], a non-selective competitive opioid receptor antagonist. Combination with naloxone is intended to reduce the abuse potential of Suboxone, as naloxone is poorly absorbed by the oral route (and has no effect when taken orally), but would reverse the opioid agonist effects of buprenorphine if injected intravenously.[A186289,F4715,F4718] Buprenorphine has poor gastrointestinal absorption and is therefore formulated as a sublingual tablet.
Indications and Usage For the treatment of moderate to severe pain, peri-operative analgesia, and opioid dependence.
Marketing Status Prescription; Discontinued
ATC Code N02AE01; N07BC01
DrugBank ID DB00921
KEGG ID D07132
MeSH ID D002047
PubChem ID 644073
TTD Drug ID D06AWE
NDC Product Code 51927-0062; 12578-607; 65724-0050; 0093-3659; 71335-0353; 42858-586; 60687-492; 62756-460; 59011-750; 65267-203; 67509-003; 12496-0100; 60687-481; 42858-353; 69238-1203; 42858-501; 59011-758; 62756-459; 71335-1154; 12496-0300; 69238-1505; 38779-3255; 59011-751; 68071-2592; 59011-757; 50090-5805; 73548-1039; 0093-3657; 0792-0631; 59011-752; 71335-0950; 69238-1202; 69238-1204; 0228-3153; 42858-502; 49812-0239; 0093-3239; 70518-1625; 42858-750; 0093-3658; 42858-493; 42858-839; 71795-2200; 0093-3656; 10920-593; 0228-3156; 12707-036; 47848-030; 69238-1205
Synonyms Buprenorphine | Buprenex | Prefin | Subutex | Buprex | Temgesic | Temgésic | 6029-M | 6029 M | 6029M | RX-6029-M | RX 6029 M | RX6029M | Buprenorphine Hydrochloride | Hydrochloride, Buprenorphine
Chemical Information
Molecular Formula C29H41NO4
CAS Registry Number 52485-79-7
SMILES CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Decreased interest19.15.02.0040.001859%Not Available
Dehydration14.05.05.001--
Delirium19.13.02.0010.004646%
Dementia17.03.01.001; 19.20.02.001--Not Available
Depressed level of consciousness17.02.04.002--
Depressed mood19.15.02.0010.004646%Not Available
Depression19.15.01.0010.023232%
Dermatitis23.03.04.0020.003717%Not Available
Dermatitis allergic23.03.04.003; 10.01.03.0140.009293%Not Available
Dermatitis contact12.03.01.040; 10.01.01.003; 23.03.04.0040.015798%Not Available
Diabetic ketoacidosis14.07.03.001; 05.07.03.001--Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.0030.006505%Not Available
Disorientation19.13.01.002; 17.02.05.0150.008363%Not Available
Disturbance in attention19.21.02.002; 17.03.03.0010.008363%
Diverticulitis11.01.07.003; 07.10.02.001--Not Available
Dizziness24.06.02.007; 02.01.02.004; 17.02.05.0030.082705%
Drug abuse19.07.02.0100.019636%Not Available
Drug dependence19.07.02.0090.112442%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Drug withdrawal syndrome19.07.02.011; 08.06.02.0040.508311%Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dysarthria19.19.03.001; 17.02.08.0010.004646%
Dysgeusia17.02.07.003; 07.14.03.001--
Dyskinesia17.01.02.0060.006505%
Dysmenorrhoea21.01.01.002--
Dyspepsia07.01.02.001--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 11 Pages